Hydrochloric Acid

Hydrochloric Acid

SCHEMBL7036110

O=C1Cc2cc(C(=O)CCl)ccc2N1.[Al+3].[Cl-].[Cl-].[Cl-]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.56
SMYD3 Q9H7B4 14/20 0.54
ALDH1A1 P00352 1/20 0.53
MAPT P10636 1/20 0.53
AHR P35869 1/20 0.51
HTR1A P08908 1/20 0.50
DRD2 P14416 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR7 P34969 1/20 0.50
DRD3 P35462 1/20 0.50
HTR2B P41595 1/20 0.50
GRIN2B Q13224 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1304506 0.97 EPHX2 (0.59) EPHX2SMYD3ALDH1A1MAPTAHR
Hydrochloric Acid SCHEMBL7036109 0.94 EPHX2 (0.56) EPHX2SMYD3ALDH1A1MAPTAHR
SCHEMBL6225349 0.87 EPHX2 (0.57) EPHX2SMYD3ALDH1A1MAPTAHR
SCHEMBL5479280 0.85 ALDH1A1 (0.59) EPHX2SMYD3ALDH1A1MAPTAHR
SCHEMBL7096246 0.84 HTR1A (0.58) EPHX2SMYD3AHRHTR1ADRD2
SCHEMBL1145012 0.84 ALDH1A1 (0.55) EPHX2SMYD3ALDH1A1MAPTHTR1A
SCHEMBL4304359 0.82 EPHX2 (0.62) EPHX2SMYD3AHRHTR1ADRD2
SCHEMBL2306726 0.82 EPHX2 (0.59) EPHX2SMYD3AHRHTR1ADRD2
Hydrochloric Acid SCHEMBL8141533 0.82 EPHX2 (0.56) EPHX2SMYD3HTR1ADRD2HTR2A
SCHEMBL5467106 0.81 MAPT (0.52) EPHX2SMYD3ALDH1A1MAPTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191128-A1 2-indolinone derivatives as modulators of protein kinase activity SUGEN, INC. 2003-10-09 US disclosed
US-6569868-B2 Imidazoly 2-indolinones as anticarcinogenic, -diabetic, -arthritic, -proliferative and inflammatory agents; fibrosis; autoimmune disorder, angiogenesis, restenosis, psoriasis, osteoarthritis and rheumatoid arthritis SUGEN, INC. 2003-05-27 US disclosed
US-20020028840-A1 2-indolinone derivatives as modulators of protein kinase activity TANG PENG CHO (US) 2002-03-07 US disclosed
US-6316635-B1 USED IN PROPHYLAXIS AND THERAPY OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER, DIABETES, AUTOIMMUNE DISORDER, HYPERPROLIFERATION DISORDER, INFLAMMATORY DISORDER, ANGIOGENESIS, RESTENOSIS, FIBROSIS, PSORIASIS, OSTEOARTHRITIS SUGEN, INC. 2001-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028840-A1 2-indolinone derivatives as modulators of protein kinase activity DMPK, IP6K2, MAP4K2 EPHX2 3944/4885SMYD3 3823/4885ALDH1A1 1871/4885
US-20030191128-A1 2-indolinone derivatives as modulators of protein kinase activity DMPK, IP6K2, MAP4K2 EPHX2 3944/4885SMYD3 3823/4885ALDH1A1 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.